## SESSION 12 12:00 – 13:15 (Hall B)

### TECHNOLOGY

| | |
|---|---|
| CGM & Pumps,<br>Jason Baker,<br>*USA* | Time in Range and Cardiometabolic risks,<br>Oliver Schnell,<br>*Germany* |
| Type 1 Diabetes: Current state of art therapy,<br>Jason Baker,<br>*USA* | |

13:15 - 13:30 Break

## SESSION 13 13:30 – 15:00 (Hall A)

### Nutrition Session

| | |
|---|---|
| Review of the dietary guidelines<br>Jaakko Tuomilehto,<br>*Finland* | Mediterranean diet<br>Rafael Gabriel,<br>*Spain* |
| Efficacy and Safety of VLCD, KETO Diets and intermittent fasting<br>Peter Gaede,<br>*Denmark* | Carb counting<br>Safaa Tawfik,<br>*Egypt* |

## SESSION 14 13:30 – 15:00 (Hall B)

### Emerging options to tackle Obesity in the context of Diabetes

| | |
|---|---|
| Obesity and its complications: No Single Specialty escapes<br>Luc Van Gaal,<br>*Belgium* | Most updated clinical trials addressing obesity<br>Jaakko Tuomilehto,<br>*Finland* |
| Evaluating incretin co-agonists<br>Melanie Davis,<br>*UK* | Tirzepatide for obesity treatment<br>Ania M. Jastreboff,<br>*USA* |

## SESSION 15 15:00 – 15:30

### A look at the Future - What's in the Pipeline?

## ACCREDITATION:

The Morehouse School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Morehouse School of Medicine designates this live activity for a maximum of up to 16 AMA PRA Category 1 Credit (s)™. Physicians should only claim credit commensurate with the extent to their participation in the activity.

MOREHOUSE SCHOOL OF MEDICINE | *Office of Extended Professional Education*

www.onlinediabetes.net/cmr

PURE SPOT EVENTS MANAGEMENT

pure.spot
www.purespot.org
info@egypure.org



Diamond Sponsor

**Boehringer Ingelheim**

# HEART, DIABETES AND KIDNEY:
## MAKE THE LINK

15 – 17 December 2022, Cairo Marriott Hotel, Egypt

**Guillermo Umpierrez**
ADA President

**Robert Eckel**
Former President of ADA

**Stefano Delprato**
EASD President

**Antonio Ceriello**
European Study Group D & CVD President

**Petar Seferovic**
Former President of HFA

+20 More

EDC Education, Dedication, Care www.onlinediabetes.net Center for Diabetes Education

MOREHOUSE SCHOOL OF MEDICINE Office of Extended Professional Education

In collaboration with

D&CVD | Diabetes Metabolism Research and Reviews

onlinediabetes.net/cmr

# DAY 1, THURSDAY, DECEMBER 15TH, 2022

8:00 – 9:00 am Registeration
9:00 – 9:15 am Welcome Remarks

## SESSION 1 9:15 – 10:30 am

### Symposium, European Study Group "Diabetes & CVD"
Theme: Heart Failure in Diabetes and Renal Disease

| | | |
|---|---|---|
| Perspectives of the cardiologist<br>Petar Seferovic, *Serbia* | Perspectives of the nephrologist<br>Per-Henrik Groop, *Finland* | Perspectives of the dialectologist<br>Paul Valensi, *France* |

## SESSION 2 10:30 – 11:30 am

### Symposium, Barts Hospital University of London and University of Rome

Theme: Diabetes Complications: are genes irrelevant?

| | | |
|---|---|---|
| Heart<br>Abraham Thomas, *USA* | Renal<br>Per-Henrik Groop, *Finland* | Diabetes on both<br>David Leslie, *UK* |

**11:30 – 12:00 Break**

## SESSION 3 12:00 – 13:30

Debate Sessions *(30 minutes for each debate)*

### Debate I Metformin is still the main foundation in treating Type 2 Diabetes

"Heart Failure in Diabetes and Renal Disease – Making the Link"

| | |
|---|---|
| No<br>Peter Gaede, *Denmark* | Yes<br>Mahmoud Ibrahim, *USA* |

### Debate II Lipid management , what after statin?

| | |
|---|---|
| Ezetimibe ± bempedoic acid<br>Robert Eckel *USA* | PCSK9 (Inclisiran)<br>Yehuda Handelsman *USA* |

### Debate III The big four in Heart Failure treatment

| | |
|---|---|
| Simultaneous<br>Petar Seferovic *Serbia* | Sequential<br>Paul Valensi *France* |

**13:30 – 14:30 Lunch Break** (Product Theatre Boehringer Ingelheim)

## SESSION 4 14:30 – 16:00

### OBESITY

| | |
|---|---|
| Weight loss or glycemic control, which comes first?<br>Samuel Klein *USA* | NAFLD: major challenge against cardiometabolic health<br>Megahed Abu Al Magd, *Egypt* |
| Obesity in the Arab Countries compared to US<br>Gamila Nasr, *Egypt*<br>Mahmoud Ibrahim, *USA* | Tirzepatide for obesity treatment<br>Ania M. Jastreboff *USA* |
| Role of Bariatric Surgery<br>Abraham Thomas, *USA* | |

# DAY 2, FRIDAY, DECEMBER 16TH, 2022

## SESSION 5 9:15 – 11:30 am

### CVOTs UPDATES DECEMBER 2022

| CVOTs Session I | CVOTs Session II | CVOTs Session III |
|---|---|---|
| "Trial Update on mineralocorticoid receptor antagonists in reducing cardio-renal disease"<br>Oliver Schnell, *Germany* | "Trial Update on SGLT2-inhibitors in reducing cardio-renal disease",<br>Paul Valensi, *France* | "Trial Update on GLP-1 RAs in reducing cardio-renal disease",<br>Peter Gaede, *Denmark* |

**11:30 – 13:00 Break** (Prayer)

## SESSION 6 13:00 – 13:20

### State of the Art lecture

New DCRM Multi Specialty recommendations
Yehuda Handelsman, *USA*

**13:20 – 14:30 Lunch Break** (Product Theatres)

## SESSION 7 14:30 – 16:00

### Established Learnings from CVOTs

| | |
|---|---|
| "Multifactorial CV risk management in diabetes: the Steno 2 trial trajectory".<br>Peter Gaede, *Denmark* | "Glycemic management in diabetes: old and new approaches".<br>Antonio Ceriello, *Italy* |
| "Role of insulin and/or severe hypoglycemia in the context of the cardio-centric approach".<br>Eberhard Standl, *Germany* | "From glucose-lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes".<br>Stefano Del Prato, *Italy* |

**17:00 – 19.00 Dinner Corporate** (Non-CME)
Boehringer Ingelheim Symposium

# DAY 3, SATURDAY, DECEMBER 17TH, 2022

(Parallel Sessions) **SESSION 8** 9:15 – 10:30 am

### Professional organizations guidelines

| | | |
|---|---|---|
| ADA Standards of Medical Care in Diabetes 2023<br>Guillermo Umpierez, *USA* | ESC & EASD Updates of Diabetes Guidelines:<br>Francesco Cosentino, *Sweden* | AACE<br>Guillermo Umpierez, *USA* |
| ESC Heart Failure Guideline 2021<br>Petar Seferovic, *Serbia* | KDIGO Diabetes Management in CKD Guideline:<br>Per-Henrik Groop, *Finland* | Barriers and opportunities to support the wider adoption of guideline-directed medical therapy (GDMT) in the real-world<br>Karim Said, *Egypt* |

## SESSION 9 10:30 – 11:30 am (HALL A)

### Cardio-Metabolic Renal diseases among special populations

| | |
|---|---|
| Women<br>*Carol Wysham, USA* | Middle Eastern<br>TBD |
| Athletes<br>Peter Gaede, *Denmark* | African Americans<br>Abraham Thomas, *USA* |

## SESSION 10 10:30 – 11:30 am (HALL B)

### LIPIDS

| | |
|---|---|
| Hypertriglyceridemia<br>*TBD* | What is beyond LDL lowering<br>Robert Eckel, *USA* |
| Omega-3 Debate<br>Jaakko Tuomilehto, *Finland* | ICOSAPENT ETHYL<br>Yehuda Handelsman, *USA* |

**11:30 – 12:00 Break**

## SESSION 11 12:00 – 13:15 (Hall A)

### Symposium: World Community for Prevention of Diabetes WCPD Cardiometabolic Prevention

| | |
|---|---|
| Early prevention of diabetic neuropathy with lifestyle intervention and antidiabetic drugs in people with prediabetes<br>Rafael Gabriel, *Spain* | The role of Epigenetics,<br>Francesco Cosentino, *Sweden* |
| Heart Failure and its Prevention, the pharmacist's roles<br>Magdy Abdel Hamid, *Egypt* | How to develop a validated CVD risk score?<br>Jaakko Tuomilehto, *Finland* |